Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 7,892 shares at $15.06 ($119K) on 2023-09-06, disclosed to the SEC on 2023-09-08.
Scheduled sale ($119k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.06 | 3,931 | $59K | 49.8% |
| 2 | $15.06 | 3,931 | $59K | 49.8% |
| 3 | $15.01 | 30 | $450 | 0.4% |
| Total | $15.06 avg | 7,892 | $119K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |